Carr-Wilkinson et al. identified a TP53 dysfunction in almost half the cases (49%) of relapsed neuroblastoma in 41 patients, with the dysfunction stemming from a TP53 mutation in 15% of the cases and an upstream defect (affecting p14ARF or MDM2) in 35% of the cases [49]. This evidence concerns the gene MDM2 and neuroblastoma.